{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:37:50Z","timestamp":1760150270114,"version":"build-2065373602"},"reference-count":42,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vaccine Strategy Office, Health and Medical Services Division, Department of Health and Medical Services, Okayama Prefectural Government"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Although many adverse reactions after SARS-CoV-2 vaccination have been reported, there have been few comprehensive studies on persistent symptoms after SARS-CoV-2 vaccination. The aim of this study was to determine the clinical characteristics of patients with various persistent symptoms after SARS-CoV-2 vaccination. Methods: A retrospective descriptive study was performed for patients who visited a specialized clinic established at Okayama University Hospital to evaluate adverse events after SARS-CoV-2 vaccination during the period from April 2021 to March 2023. Results: Descriptive analysis was performed for 121 of 127 patients who visited the clinic during the study period, and separate analysis was performed for the other 6 patients who had serious complications, who required treatment with prednisolone, and who had persistent symptoms. The median [interquartile range] age of the patients was 48 years [31\u201364 years], and the patients included 44 males (36.4%) and 77 females (63.6%). The most frequent symptoms were sensory impairment (34 patients, 28.1%), general fatigue (30 patients, 24.8%), fever\/low-grade fever (21 patients, 17.4%), and headache (21 patients, 17.4%). Serious complications included myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS), sarcoidosis, aseptic meningitis, neuromyelitis optica spectrum disorders (NMOSDs), tendon adhesions, and idiopathic thrombocytopenia. Conclusions: Although causal relationships were not determined, 15 persistent symptoms after SARS-CoV-2 vaccination were characterized. All of the symptoms had onset from 12 hours to one week after vaccination, with 10 symptoms persisting for 6 months or longer. The most frequent symptom was sensory impairment.<\/jats:p>","DOI":"10.3390\/vaccines11111661","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T12:50:42Z","timestamp":1698670242000},"page":"1661","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characteristics of Persistent Symptoms Manifested after SARS-CoV-2 Vaccination: An Observational Retrospective Study in a Specialized Clinic for Vaccination-Related Adverse Events"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9513-6864","authenticated-orcid":false,"given":"Kazuki","family":"Tokumasu","sequence":"first","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manami","family":"Fujita-Yamashita","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruhiko","family":"Sunada","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasue","family":"Sakurada","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9571-1646","authenticated-orcid":false,"given":"Koichiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9972-791X","authenticated-orcid":false,"given":"Yasuhiro","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6015-6128","authenticated-orcid":false,"given":"Yuki","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5086-1891","authenticated-orcid":false,"given":"Hideharu","family":"Hagiya","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Okayama University Hospital, Okayama 700-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-5006","authenticated-orcid":false,"given":"Hiroyuki","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7014-9095","authenticated-orcid":false,"given":"Fumio","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kitaku, Okayama 700-8558, Japan"},{"name":"Department of Infectious Diseases, Okayama University Hospital, Okayama 700-8558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jama.2021.24394","article-title":"The First 2 Years of COVID-19: Lessons to Improve Preparedness for the Next Pandemic","volume":"327","author":"Nuzzo","year":"2022","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(21)00370-6","article-title":"SARS-CoV-2 variants and ending the COVID-19 pandemic","volume":"397","author":"Fontanet","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","first-page":"1817","article-title":"WHO Declares End of COVID-19 Global Health Emergency","volume":"329","author":"Harris","year":"2023","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.p1041","article-title":"COVID-19: WHO declares end of global health emergency","volume":"381","author":"Wise","year":"2023","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12291-021-00968-z","article-title":"Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review","volume":"36","author":"Kaur","year":"2021","journal-title":"Indian J. Clin. Biochem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for Adverse Events After COVID-19 mRNA Vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jama.2021.0600","article-title":"Allergic Reactions Including Anaphylaxis after Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15510","DOI":"10.1038\/s41598-022-19936-5","article-title":"Reports of acute adverse events in mRNA COVID-19 vaccine recipients after the first and second doses in Japan","volume":"12","author":"Akaishi","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s10194-022-01400-4","article-title":"Headache onset after vaccination against SARS-CoV-2: A systematic literature review and meta-analysis","volume":"23","author":"Castaldo","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100145","DOI":"10.1016\/j.metop.2021.100145","article-title":"Serious complications of COVID-19 vaccines: A mini-review","volume":"12","author":"Fragkou","year":"2021","journal-title":"Metabol. Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.9758\/cpn.2023.21.2.222","article-title":"Neurological Adverse Reactions to SARS-CoV-2 Vaccines","volume":"21","author":"Finsterer","year":"2023","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/ene.15147","article-title":"Neurological autoimmune diseases following vaccinations against SARS-CoV-2: A case series","volume":"29","author":"Kaulen","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zucker, I., and Prendergast, B.J. (2020). Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol. Sex Differ., 11.","DOI":"10.1186\/s13293-020-00308-5"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(19)32759-X","article-title":"Raising the profile of men\u2019s health","volume":"394","author":"The","year":"2019","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3988\/jcn.2022.18.6.681","article-title":"Spectrum of Neurological Complications Following COVID-19 Vaccination in India","volume":"18","author":"Devaraj","year":"2022","journal-title":"J. Clin. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ane.13550","article-title":"Neurological side effects of SARS-CoV-2 vaccinations","volume":"145","author":"Finsterer","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s10072-022-05898-z","article-title":"SARS-CoV-2 vaccine-related neurological complications","volume":"43","author":"Oonk","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Shyu, S., Fan, H.T., Shang, S.T., Chan, J.S., Chiang, W.F., Chiu, C.C., Chen, M.H., Shyu, H.Y., and Hsiao, P.J. (2022). Clinical Manifestation, Management, and Outcomes in Patients with COVID-19 Vaccine-Induced Acute Encephalitis: Two Case Reports and a Literature Review. Vaccines, 10.","DOI":"10.3390\/vaccines10081230"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100186","DOI":"10.1016\/j.clinsp.2023.100186","article-title":"Small fiber neuropathy with long-term, multifocal paresthesias after a SARS-CoV-2 vaccination","volume":"78","author":"Finsterer","year":"2023","journal-title":"Clinics"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Morz, M. (2022). A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis after BNT162b2 mRNA Vaccination against COVID-19. Vaccines, 10.","DOI":"10.20944\/preprints202206.0308.v2"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-022-01247-x","article-title":"Neurological Complications Following COVID-19 Vaccination","volume":"23","author":"Chatterjee","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.5603\/PJNNS.a2022.0049","article-title":"COVID-19-related headache and innate immune response\u2014A narrative review","volume":"57","author":"Straburzynski","year":"2023","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"994140","DOI":"10.3389\/fpain.2022.994140","article-title":"Post COVID-19 vaccination headache: A clinical and epidemiological evaluation","volume":"3","author":"Ceccardi","year":"2022","journal-title":"Front. Pain Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"953","DOI":"10.7326\/0003-4819-121-12-199412150-00009","article-title":"The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group","volume":"121","author":"Fukuda","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1300\/J092v11n01_02","article-title":"Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome","volume":"11","author":"Carruthers","year":"2003","journal-title":"J. Chronic Fatigue Syndr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2015.1346","article-title":"Beyond myalgic encephalomyelitis\/chronic fatigue syndrome: An IOM report on redefining an illness","volume":"313","author":"Clayton","year":"2015","journal-title":"JAMA"},{"key":"ref_29","first-page":"e32433","article-title":"A Case Report: Long Post-COVID Vaccination Syndrome during the Eleven Months after the Third Moderna Dose","volume":"14","author":"Finsterer","year":"2022","journal-title":"Cureus"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"23247096221086450","DOI":"10.1177\/23247096221086450","article-title":"COVID-19 mRNA Vaccine-Associated Uveitis Leading to Diagnosis of Sarcoidosis: Case Report and Review of Literature","volume":"10","author":"Matsuo","year":"2022","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1620\/tjem.234.137","article-title":"A Japanese patient with Lofgren\u2019s syndrome with an HLA-DR12 allele and review of literature on Japanese patients","volume":"234","author":"Ishimatsu","year":"2014","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1007\/s00259-021-05360-w","article-title":"Beyond COVID-19 vaccination-associated pitfalls on [(18)F]Fluorodeoxyglucose (FDG) PET: A case of a concomitant sarcoidosis","volume":"48","author":"Bauckneht","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.12998\/wjcc.v11.i1.177","article-title":"Drug-induced sarcoidosis-like reaction three months after BNT162b2 mRNA COVID-19 vaccination: A case report and review of literature","volume":"11","author":"Kim","year":"2023","journal-title":"World J. Clin. Cases"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/09674845.2016.1159047","article-title":"Aseptic meningitis after measles-mumps-rubella (MMR) vaccination","volume":"73","author":"Mamishi","year":"2016","journal-title":"Br. J. Biomed. Sci."},{"key":"ref_35","unstructured":"ISO (2018). Traditional Chinese Medicine\u2014Controlled Vocabulary Index on Japanese Kampo Formulas and Indication Codes for Products, International Organization for Standardization."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1007\/s10072-021-05543-1","article-title":"Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine","volume":"42","author":"Saito","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bogs, T., Saleh, N., Yavuz, S.T., Fazeli, W., Ganschow, R., and Schreiner, F. (2022). Aseptic Meningitis, Mucocutaneous Lesions and Arthritis after COVID-19 Vaccination in a 15-Year-Old Boy. Vaccines, 10.","DOI":"10.3390\/vaccines10020325"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100406","DOI":"10.1016\/j.bbih.2021.100406","article-title":"Aseptic meningitis after BNT-162b2 COVID-19 vaccination","volume":"19","author":"Chan","year":"2022","journal-title":"Brain Behav. Immun. Health"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1099758","DOI":"10.3389\/fneur.2023.1099758","article-title":"New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: A systematic review","volume":"14","author":"Harel","year":"2023","journal-title":"Front. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"859926","DOI":"10.3389\/fimmu.2022.859926","article-title":"Case Report: New-Onset Rheumatoid Arthritis Following COVID-19 Vaccination","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/annrheumdis-2021-221571","article-title":"Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong","volume":"81","author":"Li","year":"2022","journal-title":"Ann. Rheum Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/11\/1661\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:14:17Z","timestamp":1760130857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/11\/1661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["vaccines11111661"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11111661","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}